Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.52 |
| ▸ | CA2 | P00918 | 5/20 | 0.52 |
| ▸ | SELP | P16109 | 1/20 | 0.48 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 7/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.45 |
| ▸ | HDAC10 | Q969S8 | 6/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.45 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.43 |
| ▸ | SUCNR1 | Q9BXA5 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13900421 | 0.94 | CA1 (0.45) | CA1CA2SELPSOAT1HDAC3 | |
| SCHEMBL4051518 | 0.78 | KCNA5 (0.50) | SUCNR1 | |
| SCHEMBL15284544 | 0.77 | CA1 (0.59) | CA1CA2HDAC3HDAC1HDAC2 | |
| SCHEMBL4060683 | 0.76 | KCNA5 (0.50) | HDAC1HDAC10HDAC6SUCNR1 | |
| SCHEMBL16747675 | 0.76 | GAA (0.61) | CA1CA2TDP1 | |
| SCHEMBL4051645 | 0.76 | CA1 (0.58) | CA1CA2HDAC3HDAC1HDAC2 | |
| SCHEMBL6831601 | 0.75 | SOAT1 (0.44) | CA1CA2SOAT1HDAC3HDAC1 | |
| SCHEMBL21326534 | 0.74 | ALDH1A1 (0.56) | — | |
| SCHEMBL18535719 | 0.74 | BRD9 (0.50) | — | |
| SCHEMBL5277825 | 0.74 | CA1 (0.62) | CA1CA2HDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7507753-B2 | melanocortin receptor agonist, antagonist; preventing or treating inflammatory diseases, AIDS, obesity, bulimia, anorexia or sexual dysfunction; N-(2-aminoethyl)-3'-[1-{N-(1-benzylpiperidin-4-yl)-N-(2-naphthylacetyl)aminoethyl][1,1'-biphenyl)-2-carboxamide dihydrochloride | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2009-03-24 | — | — | US | disclosed |
| US-20050096359-A1 | melanocortin receptor agonist, antagonist; preventing or treating inflammatory diseases, AIDS, obesity, bulimia, anorexia or sexual dysfunction; N-(2-aminoethyl)-3'-[1-{N-(1-benzylpiperidin-4-yl)-N-(2-naphthylacetyl)aminoethyl][1,1'-biphenyl)-2-carboxamide dihydrochloride | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-05 | — | — | US | disclosed |
| EP-1466904-A1 | BIARYL COMPOUND AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096359-A1 | melanocortin receptor agonist, antagonist; preventing or treating inflammatory diseases, AIDS, obesity, bulimia, anorexia or sexual dysfunction; N-(2-aminoethyl)-3'-[1-{N-(1-benzylpiperidin-4-yl)-N-(2-naphthylacetyl)aminoethyl][1,1'-biphenyl)-2-carboxamide dihydrochloride | MC4R, MC3R, MC1R | CA1 4534/4885CA2 3125/4885SELP 1431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.